Correction: Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of nasopharyngeal carcinoma cells

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Novel Affibody Molecules Targeting the HPV16 E6 Oncoprotein Inhibited the Proliferation of Cervical Cancer Cells

“…In our previous study, a 14-kDa high-purity HPV16 E6 recombinant protein was prepared ( Zhang et al, 2020 ) and used as a target protein during selection. Screening for potential HPV16 E6-binding affibodies was conducted following protocols established in our laboratory, which are described in detail in several previous studies ( Xue et al, 2016 ; Zhu J. et al, 2020 ; Zhu S. et al, 2020 ). After pressure biopanning, phage-based ELISA screening and DNA sequencing, the sequences derived from inserted fragments in selected phage clones were potential affibody molecules with elevated affinity for HPV16 E6.…”

“…A surface plasmon resonance (SPR) assay was conducted to assess the binding ability of Z HPV16E6 affibodies to recombinant HPV16 E6 on a BIAcore T200 (GE Healthcare, Uppsala, Sweden) as previously described ( Zhu J. et al, 2020 ). As a negative control, affibody Z WT was used.…”

“…An indirect immunofluorescence assay (IFA) was performed following previously protocols ( Zhu J. et al, 2020 ). Briefly, we evenly cultured TC-1, CaSki, HeLa229, and C666-1 cells on coverslips in 6-well cell culture plates, and subjected them to a 6-h incubation with the Z HPV16E6 affibodies or Z WT affibody control, with a final concentration at 100 μg/ml.…”

“…CaSki cells seeded at 1 × 10 5 per well in 6-well plates were incubated with medium containing either Z HPV16E6 1235 or Z WT or medium alone for the indicated time. Equal amounts of protein (30 μg) were evaluated using the Western blot technique with reference to a previously highlighted protocol ( Zhu J. et al, 2020 ). In addition, we have listed all the primary antibodies in Supplementary Table 1 .…”

“…To date, over 500 studies have been published in which affibody molecules targeting approximately 50 different proteins have been isolated and serve as high-affinity ligands in a variety of applications 1 . The affibody-targeted proteins, including HER2 (human epidermal growth factor receptor 2; Orlova et al, 2006 ), EGFR (epidermal growth factor receptor; Wu et al, 2020 ), TNF-α (tumor necrosis factor-α; Löfdahl et al, 2009 ), and transcription factor c-Jun ( Lundberg et al, 2009 ), as well as EBV LMP2 (Epstein-Barr virus latent membrane protein 2; Zhu J. et al, 2020 ; Zhu S. et al, 2020 ) and HPV16 E7 (human papillomavirus type 16 E7; Xue et al, 2016 ; Jiang et al, 2018 ), which have been reported by our research team.…”